<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7147535\results\search\disease\results.xml">
  <result pre="International PublishingCham pmcid: 7147535514 doi: 10.1007/s40257-020-00514-2 : Current Opinion Managing" exact="Cutaneous" post="Immune-Mediated Diseases During theÂ COVID-19 Pandemic http://orcid.org/0000-0003-0404-0870TorresTiagotorres.tiago@outlook.com12http://orcid.org/0000-0001-6083-0952PuigLuis3[1], grid.5808.50000 0001"/>
  <result pre="pmcid: 7147535514 doi: 10.1007/s40257-020-00514-2 : Current Opinion Managing Cutaneous Immune-Mediated" exact="Diseases" post="During theÂ COVID-19 Pandemic http://orcid.org/0000-0003-0404-0870TorresTiagotorres.tiago@outlook.com12http://orcid.org/0000-0001-6083-0952PuigLuis3[1], grid.5808.50000 0001 1503 7226Department"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="(WHO) declaration of COVID-19 as a global pandemic. Abstract Coronavirus" exact="disease" post="2019 (COVID-19) is a clinical syndrome caused by a"/>
  <result pre="global pandemic. Abstract Coronavirus disease 2019 (COVID-19) is a clinical" exact="syndrome" post="caused by a novel coronavirus called severe acute respiratory"/>
  <result pre="a clinical syndrome caused by a novel coronavirus called severe" exact="acute" post="respiratory syndrome coronavirus 2Â (SARS-CoV-2). COVID-19 has spread rapidly"/>
  <result pre="clinical syndrome caused by a novel coronavirus called severe acute" exact="respiratory" post="syndrome coronavirus 2Â (SARS-CoV-2). COVID-19 has spread rapidly worldwide"/>
  <result pre="syndrome caused by a novel coronavirus called severe acute respiratory" exact="syndrome" post="coronavirus 2Â (SARS-CoV-2). COVID-19 has spread rapidly worldwide and"/>
  <result pre="by the World Health Organization on 11 March, 2020. SARS-CoV-2" exact="infection" post="in severe cases involves the host response as an"/>
  <result pre="involves the host response as an important contributor to the" exact="disease" post="process and tissue damage, mainly due to dysregulated and"/>
  <result pre="mainly due to dysregulated and excessive innate immune responses. The" exact="primary" post="immune response leads to viral clearance in the majority"/>
  <result pre="excessive innate immune responses. The primary immune response leads to" exact="viral" post="clearance in the majority of cases. However, in a"/>
  <result pre="majority of cases. However, in a subgroup of patients, the" exact="secondary" post="immune response may be exaggerated, leading to inflammatory-induced lung"/>
  <result pre="leading to inflammatory-induced lung injury and other complications including pneumonitis," exact="acute" post="respiratory distress syndrome, respiratory failure, shock, organ failure, and"/>
  <result pre="to inflammatory-induced lung injury and other complications including pneumonitis, acute" exact="respiratory" post="distress syndrome, respiratory failure, shock, organ failure, and potentially"/>
  <result pre="injury and other complications including pneumonitis, acute respiratory distress syndrome," exact="respiratory" post="failure, shock, organ failure, and potentially death. Several cutaneous"/>
  <result pre="syndrome, respiratory failure, shock, organ failure, and potentially death. Several" exact="cutaneous" post="immune-mediated diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa,"/>
  <result pre="failure, and potentially death. Several cutaneous immune-mediated diseases, including psoriasis," exact="atopic dermatitis," post="and hidradenitis suppurativa, are therapeutically managed with biologic and"/>
  <result pre="death. Several cutaneous immune-mediated diseases, including psoriasis, atopic dermatitis, and" exact="hidradenitis suppurativa," post="are therapeutically managed with biologic and non-biologic immunosuppressive and"/>
  <result pre="drugs. The outbreak of COVID-19 affects the management of these" exact="chronic" post="conditions, not only for those who are already receiving"/>
  <result pre="to control their disease. In this article, the management of" exact="cutaneous" post="immune-mediated diseases during the COVID-19 pandemic is discussed. Key"/>
  <result pre="COVID-19 pandemic is discussed. Key message The outbreak of coronavirus" exact="disease" post="2019 (COVID-19) affects the management of several cutaneous immune-mediated"/>
  <result pre="of coronavirus disease 2019 (COVID-19) affects the management of several" exact="cutaneous" post="immune-mediated chronic diseases, including psoriasis, atopic dermatitis, and hidradenitis"/>
  <result pre="disease 2019 (COVID-19) affects the management of several cutaneous immune-mediated" exact="chronic" post="diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa, not"/>
  <result pre="the management of several cutaneous immune-mediated chronic diseases, including psoriasis," exact="atopic dermatitis," post="and hidradenitis suppurativa, not only for those who are"/>
  <result pre="several cutaneous immune-mediated chronic diseases, including psoriasis, atopic dermatitis, and" exact="hidradenitis suppurativa," post="not only for those who are already receiving treatment"/>
  <result pre="excessive innate immune response is an important contributor to the" exact="disease" post="process and tissue damage in severe cases of severe"/>
  <result pre="disease process and tissue damage in severe cases of severe" exact="acute" post="respiratory syndrome coronavirus 2 infection. Some selective immunosuppressants or"/>
  <result pre="process and tissue damage in severe cases of severe acute" exact="respiratory" post="syndrome coronavirus 2 infection. Some selective immunosuppressants or immunomodulatory"/>
  <result pre="and tissue damage in severe cases of severe acute respiratory" exact="syndrome" post="coronavirus 2 infection. Some selective immunosuppressants or immunomodulatory drugs"/>
  <result pre="â€œcytokine stormâ€� associated with a poor outcome of COVID-19. Coronavirus" exact="disease" post="2019 (COVID-19) is a clinical syndrome caused by a"/>
  <result pre="outcome of COVID-19. Coronavirus disease 2019 (COVID-19) is a clinical" exact="syndrome" post="caused by a novel coronavirus called severe acute respiratory"/>
  <result pre="a clinical syndrome caused by a novel coronavirus called severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). On 31 December, 2019,"/>
  <result pre="clinical syndrome caused by a novel coronavirus called severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). On 31 December, 2019, a"/>
  <result pre="syndrome caused by a novel coronavirus called severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). On 31 December, 2019, a cluster"/>
  <result pre="coronavirus 2 (SARS-CoV-2). On 31 December, 2019, a cluster of" exact="pneumonia" post="cases of unknown etiology was reported in Wuhan, Hubei"/>
  <result pre="Province, China. On 9 January, 2020, the China Center for" exact="Disease" post="Control and Prevention reported a novel coronavirus as the"/>
  <result pre="been reported worldwide [2]. Although COVID-19 appears to have a" exact="lower" post="severity and mortality rate than two other previous human"/>
  <result pre="and mortality rate than two other previous human coronavirus (CoV)" exact="infections" post="(SARS-CoV and MERS-CoV), a subgroup of patients (particularly elderly"/>
  <result pre="people and those with underlying medical co-morbidities) develop a severe" exact="disease" post="characterized by interstitial pneumonia and the rapid development of"/>
  <result pre="underlying medical co-morbidities) develop a severe disease characterized by interstitial" exact="pneumonia" post="and the rapid development of acute respiratory distress syndrome"/>
  <result pre="disease characterized by interstitial pneumonia and the rapid development of" exact="acute" post="respiratory distress syndrome or septic shock with high levels"/>
  <result pre="characterized by interstitial pneumonia and the rapid development of acute" exact="respiratory" post="distress syndrome or septic shock with high levels of"/>
  <result pre="interstitial pneumonia and the rapid development of acute respiratory distress" exact="syndrome" post="or septic shock with high levels of acute-phase reactants"/>
  <result pre="and the rapid development of acute respiratory distress syndrome or" exact="septic shock" post="with high levels of acute-phase reactants [3, 4]. Highly"/>
  <result pre="levels of acute-phase reactants [3, 4]. Highly pathogenic human CoV" exact="infections" post="suppress type I interferon (IFN) production and signaling, the"/>
  <result pre="acute-phase reactants [3, 4]. Highly pathogenic human CoV infections suppress" exact="type I" post="interferon (IFN) production and signaling, the key component of"/>
  <result pre="component of host antiviral defense in the early phase of" exact="viral" post="replication, thus exacerbating disease progression [5]. In line with"/>
  <result pre="defense in the early phase of viral replication, thus exacerbating" exact="disease" post="progression [5]. In line with SARS and MERS, SARS-CoV-2"/>
  <result pre="disease progression [5]. In line with SARS and MERS, SARS-CoV-2" exact="infection" post="in severe cases involves the host response as an"/>
  <result pre="involves the host response as an important contributor to the" exact="disease" post="process and tissue damage, mainly due to dysregulated and"/>
  <result pre="mainly due to dysregulated and excessive innate immune responses. The" exact="primary" post="immune response leads to viral clearance in most cases."/>
  <result pre="excessive innate immune responses. The primary immune response leads to" exact="viral" post="clearance in most cases. However, for reasons that are"/>
  <result pre="that are still unclear, in a subgroup of patients, the" exact="secondary" post="immune response may be exaggerated, leading to inflammatory-induced lung"/>
  <result pre="exaggerated, leading to inflammatory-induced lung injury and complications including pneumonitis," exact="acute" post="respiratory distress syndrome, respiratory failure, shock, organ failure, and"/>
  <result pre="leading to inflammatory-induced lung injury and complications including pneumonitis, acute" exact="respiratory" post="distress syndrome, respiratory failure, shock, organ failure, and potentially"/>
  <result pre="lung injury and complications including pneumonitis, acute respiratory distress syndrome," exact="respiratory" post="failure, shock, organ failure, and potentially death [6]. This"/>
  <result pre="response is considered a â€œcytokine stormâ€� similar to that of" exact="secondary" post="hemophagocytic histiocytosis, which leads to an hyperinflammation state, with"/>
  <result pre="to an hyperinflammation state, with unremitting fever, cytopenias, hyperferritinemia, and" exact="pulmonary" post="involvement (including acute respiratory distress syndrome) in 50% of"/>
  <result pre="state, with unremitting fever, cytopenias, hyperferritinemia, and pulmonary involvement (including" exact="acute" post="respiratory distress syndrome) in 50% of cases [7]. The"/>
  <result pre="with unremitting fever, cytopenias, hyperferritinemia, and pulmonary involvement (including acute" exact="respiratory" post="distress syndrome) in 50% of cases [7]. The cytokine"/>
  <result pre="[7]. The cytokine profile associated with COVID-19 is characterized by" exact="elevated serum" post="levels of multiple cytokines [3], probably produced by highly"/>
  <result pre="produced by highly inflammatory macrophages [8]. Interleukin (IL)-6, IL-10, and" exact="tumor" post="necrosis factor (TNF)-Î± surge during illness and decline upon"/>
  <result pre="decreased IFN-Î³ expression in CD4+ cells, and correlates with the" exact="disease" post="severity of COVID-19 [8, 9]. In severe cases, marked"/>
  <result pre="occurring in 20% of patients in the course of the" exact="disease" post="[11]. Hospitalization, generally due to pneumonitis, occurred in 30%"/>
  <result pre="30% of cases; severe illness (requiring intensive care unit and/or" exact="respiratory" post="support) was reported in 15% of hospitalized cases, and"/>
  <result pre="in patients aged 60Â years and above [1]. Pulse oximetry," exact="respiratory" post="frequency, and chest X-ray films determine the clinical management"/>
  <result pre="60Â years and above [1]. Pulse oximetry, respiratory frequency, and" exact="chest" post="X-ray films determine the clinical management of patients and"/>
  <result pre="the clinical management of patients and the need for hospitalization." exact="Multiple" post="therapeutic approaches have been proposed and are being studied"/>
  <result pre="agents, and anti-IL-6 drugs such as tocilizumab [17, 18]. Several" exact="cutaneous" post="immune-mediated diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa,"/>
  <result pre="as tocilizumab [17, 18]. Several cutaneous immune-mediated diseases, including psoriasis," exact="atopic dermatitis," post="and hidradenitis suppurativa, are therapeutically managed with biologic and"/>
  <result pre="18]. Several cutaneous immune-mediated diseases, including psoriasis, atopic dermatitis, and" exact="hidradenitis suppurativa," post="are therapeutically managed with biologic and non-biologic immunosuppressive and"/>
  <result pre="drugs. The outbreak of COVID-19 affects the management of these" exact="chronic" post="conditions, not only for those who are already receiving"/>
  <result pre="no available evidence that supports discontinuation of biologic treatment of" exact="psoriasis" post="for most patients simply because of the risk of"/>
  <result pre="psoriasis for most patients simply because of the risk of" exact="infection" post="[24]. According to the results of randomized clinical trials"/>
  <result pre="clinical trials of biological agents in psoriasis, the rates of" exact="nasopharyngitis" post="and upper respiratory tract infections are similar to placebo"/>
  <result pre="of biological agents in psoriasis, the rates of nasopharyngitis and" exact="upper" post="respiratory tract infections are similar to placebo [25]. Some"/>
  <result pre="biological agents in psoriasis, the rates of nasopharyngitis and upper" exact="respiratory" post="tract infections are similar to placebo [25]. Some authors"/>
  <result pre="in psoriasis, the rates of nasopharyngitis and upper respiratory tract" exact="infections" post="are similar to placebo [25]. Some authors have proposed"/>
  <result pre="anti-IL biologics (â€œlikely moderate riskâ€�) in the presence of mild" exact="viral" post="symptoms [26]. Other authors recommend a limitation or avoidance"/>
  <result pre="and TNFÎ± inhibitors for dermatologic patients in areas with high" exact="infection" post="rates and stopping all immunosuppressive and biological therapy when"/>
  <result pre="require more stringent precautions [28]. In rheumatology, poor control of" exact="rheumatoid arthritis" post="might imply an even greater infectious risk factor than"/>
  <result pre="more stringent precautions [28]. In rheumatology, poor control of rheumatoid" exact="arthritis" post="might imply an even greater infectious risk factor than"/>
  <result pre="poor control of rheumatoid arthritis might imply an even greater" exact="infectious" post="risk factor than continuation of treatment [29], and the"/>
  <result pre="factor than continuation of treatment [29], and the use of" exact="systemic" post="corticosteroids might contribute to viral replication in the event"/>
  <result pre="[29], and the use of systemic corticosteroids might contribute to" exact="viral" post="replication in the event of SARS-CoV-2 infection [30]. Immunosuppressive"/>
  <result pre="might contribute to viral replication in the event of SARS-CoV-2" exact="infection" post="[30]. Immunosuppressive medications in transplanted patients increase the risk"/>
  <result pre="medications in transplanted patients increase the risk or duration of" exact="infections" post="caused by viral agents, such as adenovirus, influenza, norovirus,"/>
  <result pre="patients increase the risk or duration of infections caused by" exact="viral" post="agents, such as adenovirus, influenza, norovirus, rhinovirus, or respiratory"/>
  <result pre="by viral agents, such as adenovirus, influenza, norovirus, rhinovirus, or" exact="respiratory" post="syncytial virus [31]; the same effect does not seem"/>
  <result pre="the same effect does not seem to be observed for" exact="infections" post="caused by the coronavirus family. Similarly to SARS-CoV and"/>
  <result pre="demonstrated that for patients in the follow-up for cirrhosis, transplantation," exact="autoimmune liver disease," post="or chemotherapy for hepatoblastoma, despite some testing positive for"/>
  <result pre="that for patients in the follow-up for cirrhosis, transplantation, autoimmune" exact="liver disease," post="or chemotherapy for hepatoblastoma, despite some testing positive for"/>
  <result pre="hepatoblastoma, despite some testing positive for SARS-CoV-2, none developed clinical" exact="pulmonary" post="disease [34]. Some selective immunosuppressants or immunomodulatory drugs might"/>
  <result pre="despite some testing positive for SARS-CoV-2, none developed clinical pulmonary" exact="disease" post="[34]. Some selective immunosuppressants or immunomodulatory drugs might be"/>
  <result pre="the â€œcytokine stormâ€� associated with a poor outcome of COVID-19." exact="Tumor" post="necrosis factor-Î± levels are moderately increased in patients with"/>
  <result pre="have been observed in patients with COVID-19 and correlate with" exact="disease" post="severity [35]. Tumor necrosis factor inhibitors might be effective"/>
  <result pre="in patients with COVID-19 and correlate with disease severity [35]." exact="Tumor" post="necrosis factor inhibitors might be effective in reducing SARS-CoV2"/>
  <result pre="Tumor necrosis factor inhibitors might be effective in reducing SARS-CoV2" exact="infection" post="and the associated organ damage, by decreasing TNF-Î±-converting enzyme-dependent"/>
  <result pre="into the cell [36]. A study evaluating adalimumab in COVID-19" exact="infection" post="has recently been registered in the Chinese Clinical Trial"/>
  <result pre="antiviral immune responses, but it may also promote and exacerbate" exact="viral" post="illnesses, especially through antagonism of regulatory T-cell function, which"/>
  <result pre="of regulatory T-cell function, which is of paramount importance in" exact="viral" post="infections of the respiratory tract [37]. An elevated Th17"/>
  <result pre="regulatory T-cell function, which is of paramount importance in viral" exact="infections" post="of the respiratory tract [37]. An elevated Th17 response"/>
  <result pre="which is of paramount importance in viral infections of the" exact="respiratory" post="tract [37]. An elevated Th17 response has also been"/>
  <result pre="contribute to the â€œcytokine stormâ€�, resulting in tissue damage and" exact="pulmonary" post="edema. Extremely high numbers of CCR6Ã¾ Th17 cells in"/>
  <result pre="edema. Extremely high numbers of CCR6Ã¾ Th17 cells in the" exact="peripheral" post="blood of a patient with severe COVID-19 support the"/>
  <result pre="COVID-19 support the role of the Th17 pathway in this" exact="disease" post="[40]. Many psoriasis treatments inhibit the IL-17 pathway directly"/>
  <result pre="role of the Th17 pathway in this disease [40]. Many" exact="psoriasis" post="treatments inhibit the IL-17 pathway directly (IL-17A and IL-17R"/>
  <result pre="and IL-17R inhibitors) and indirectly (IL-23 inhibitors). Low levels of" exact="type I" post="IFN seem to be common to COVID-19, SARS, and"/>
  <result pre="of dupilumab, an IL-4/IL-13 inhibitor used in the treatment of" exact="atopic dermatitis," post="to mitigate the â€œcytokine stormâ€� seen in some patients"/>
  <result pre="Administration and the European Medicines Agency for the treatment of" exact="atopic dermatitis," post="has been predicted to reduce the ability of the"/>
  <result pre="and cyclin G-associated kinase (GAK), which are both involved in" exact="viral" post="endocytosis [42]. Baricitinib appears to be able to effectively"/>
  <result pre="concentration obtained with the submitted dosage for the treatment of" exact="atopic dermatitis" post="(2â€&quot;4Â mg daily), as well as reducing IL-6 and"/>
  <result pre="obtained with the submitted dosage for the treatment of atopic" exact="dermatitis" post="(2â€&quot;4Â mg daily), as well as reducing IL-6 and"/>
  <result pre="may be responsible for the more severe forms of interstitial" exact="pneumonia" post="due to COVID-19 [42, 43]. However, the inhibition of"/>
  <result pre="with COVID-19 unless indicated for other reasons (i.e., exacerbation of" exact="asthma" post="or chronic obstructive pulmonary disease, septic shock) because they"/>
  <result pre="COVID-19 unless indicated for other reasons (i.e., exacerbation of asthma" exact="or chronic" post="obstructive pulmonary disease, septic shock) because they might exacerbate"/>
  <result pre="unless indicated for other reasons (i.e., exacerbation of asthma or" exact="chronic" post="obstructive pulmonary disease, septic shock) because they might exacerbate"/>
  <result pre="for other reasons (i.e., exacerbation of asthma or chronic obstructive" exact="pulmonary" post="disease, septic shock) because they might exacerbate COVID-19-associated lung"/>
  <result pre="immunosuppressed patients are not at an increased risk for severe" exact="disease" post="and complications compared with the general population and that"/>
  <result pre="with a poorer outcome in these patients. Thus, patients with" exact="cutaneous" post="immune-mediated diseases (including psoriasis, atopic dermatitis, and hidradenitis suppurativa)"/>
  <result pre="these patients. Thus, patients with cutaneous immune-mediated diseases (including psoriasis," exact="atopic dermatitis," post="and hidradenitis suppurativa) can continue their treatment even during"/>
  <result pre="patients with cutaneous immune-mediated diseases (including psoriasis, atopic dermatitis, and" exact="hidradenitis" post="suppurativa) can continue their treatment even during the COVID-19"/>
  <result pre="can continue their treatment even during the COVID-19 outbreak, preventing" exact="disease" post="flares that can contribute to an increasing patient burden,"/>
  <result pre="administration intervals or temporary treatment discontinuation. Comorbidities associated with psoriasis," exact="hidradenitis suppurativa," post="and atopic dermatitis (obesity, cardiovascular disease or risk factors,"/>
  <result pre="temporary treatment discontinuation. Comorbidities associated with psoriasis, hidradenitis suppurativa, and" exact="atopic dermatitis" post="(obesity, cardiovascular disease or risk factors, chronic lung disease,"/>
  <result pre="treatment discontinuation. Comorbidities associated with psoriasis, hidradenitis suppurativa, and atopic" exact="dermatitis" post="(obesity, cardiovascular disease or risk factors, chronic lung disease,"/>
  <result pre="Comorbidities associated with psoriasis, hidradenitis suppurativa, and atopic dermatitis (obesity," exact="cardiovascular disease" post="or risk factors, chronic lung disease, and asthma) and"/>
  <result pre="associated with psoriasis, hidradenitis suppurativa, and atopic dermatitis (obesity, cardiovascular" exact="disease" post="or risk factors, chronic lung disease, and asthma) and"/>
  <result pre="suppurativa, and atopic dermatitis (obesity, cardiovascular disease or risk factors," exact="chronic" post="lung disease, and asthma) and age older than 60Â"/>
  <result pre="and atopic dermatitis (obesity, cardiovascular disease or risk factors, chronic" exact="lung disease," post="and asthma) and age older than 60Â years worsen"/>
  <result pre="receiving immunosuppressive or biologic treatment for dermatologic indications, including psoriasis," exact="atopic dermatitis," post="and hidradenitis suppurativa. Author contribution TT and LP both"/>
  <result pre="biologic treatment for dermatologic indications, including psoriasis, atopic dermatitis, and" exact="hidradenitis suppurativa." post="Author contribution TT and LP both had the idea"/>
  <result pre="Sandoz, Samsung-Bioepis, Sanofi, and UCB. References References 1.European Centre for" exact="Disease" post="Prevention and Control. Rapid risk assessment: coronavirus disease 2019"/>
  <result pre="Centre for Disease Prevention and Control. Rapid risk assessment: coronavirus" exact="disease" post="2019 (COVID-19) pandemic: increased transmission in the EU/EEA and"/>
  <result pre="2020. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-coronavirus-disease-2019-covid-19-pandemic. Accessed 1 Apr 2020. 2.World Health Organization. Coronavirus" exact="disease" post="(COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 1 Apr 2020. 3.HuangCWangYLiXet al.Clinical"/>
  <result pre="https://www.ncbi.nlm.nih.gov/books/NBK554776/. Accessed 1 Apr 2020. 5.FungS-YYuenK-SYeZ-Wet al.A tug-of-war between severe" exact="acute" post="respiratory syndrome coronavirus 2 and host antiviral defence: lessons"/>
  <result pre="Accessed 1 Apr 2020. 5.FungS-YYuenK-SYeZ-Wet al.A tug-of-war between severe acute" exact="respiratory" post="syndrome coronavirus 2 and host antiviral defence: lessons from"/>
  <result pre="1 Apr 2020. 5.FungS-YYuenK-SYeZ-Wet al.A tug-of-war between severe acute respiratory" exact="syndrome" post="coronavirus 2 and host antiviral defence: lessons from other"/>
  <result pre="9.ChenGWuDGuoWet al.Clinical and immunologic features in severe and moderate coronavirus" exact="disease" post="2019J Clin Invest.202010.1172/JCI13724432255767 10.QinCZhouLHuZet al.Dysregulation of immune response in"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis.202010.1093/cid/ciaa23732161968 14.ZhouDDaiS-MTongQCOVID-19: a"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis.202010.1093/cid/ciaa23732161968 14.ZhouDDaiS-MTongQCOVID-19: a recommendation"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis.202010.1093/cid/ciaa23732161968 14.ZhouDDaiS-MTongQCOVID-19: a recommendation to"/>
  <result pre="a recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progressionJ Antimicrob Chemother.202010.1093/jac/dkaa11432196083 15.KimAHJSparksJALiewJWet al.A rush to judgment?"/>
  <result pre="anti-inflammatory drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): the experience of clinical immunologists from ChinaClin"/>
  <result pre="the experience of clinical immunologists from ChinaClin Immunol20202521410839310.1016/j.clim.2020.108393 17.Sarzi-PuttiniPCeribelliAMarottoDet al.Systemic" exact="rheumatic" post="diseases: from biological agents to small moleculesAutoimmun Rev201918658359210.1016/j.autrev.2018.12.00930959214 18.FerroFElefanteEBaldiniCet"/>
  <result pre="2020. 23.IOIBD. IOIBD update on COVID19 for patients with Crohnâ€™s" exact="disease" post="and ulcerative colitis. https://www.ioibd.org/ioibd-update-on-covid19-for-patients-with-crohns-disease-and-ulcerative-colitis/. Accessed 1 Apr 2020. 24.BashyamAMFeldmanSRShould"/>
  <result pre="IOIBD update on COVID19 for patients with Crohnâ€™s disease and" exact="ulcerative colitis." post="https://www.ioibd.org/ioibd-update-on-covid19-for-patients-with-crohns-disease-and-ulcerative-colitis/. Accessed 1 Apr 2020. 24.BashyamAMFeldmanSRShould patients stop their"/>
  <result pre="treatment during the COVID-19 pandemicJ Dermatolog Treat2020191210.1080/09546634.2020.1742438 25.LebwohlMRivera-OyolaRMurrellDFShould biologics for" exact="psoriasis" post="be interrupted in the era of COVID-19?J Am Acad"/>
  <result pre="treatment with immunosuppressants? A call for actionDermatol Ther202011e1329810.1111/dth.13298 28.ShahPZampellaJGUse of" exact="systemic" post="immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemicJ"/>
  <result pre="actionDermatol Ther202011e1329810.1111/dth.13298 28.ShahPZampellaJGUse of systemic immunomodulatory therapies during the coronavirus" exact="disease" post="2019 (COVID-19) pandemicJ Am Acad Dermatol.202010.1016/j.jaad.2020.03.05632244021 29.FavalliEGIngegnoliFDe LuciaOet al.COVID-19"/>
  <result pre="disease 2019 (COVID-19) pandemicJ Am Acad Dermatol.202010.1016/j.jaad.2020.03.05632244021 29.FavalliEGIngegnoliFDe LuciaOet al.COVID-19" exact="infection" post="and rheumatoid arthritis: faraway, so close!Autoimmun Rev20202010252310.1016/j.autrev.2020.102523 30.RussellCDMillarJEBaillieJKClinical evidence"/>
  <result pre="does not support corticosteroid treatment for 2019-nCoV lung injuryLancet20203951022347347510.1016/S0140-6736(20)30317-232043983 31.KaltsasASepkowitzKCommunity" exact="acquired" post="respiratory and gastrointestinal viral infections: challenges in the immunocompromised"/>
  <result pre="not support corticosteroid treatment for 2019-nCoV lung injuryLancet20203951022347347510.1016/S0140-6736(20)30317-232043983 31.KaltsasASepkowitzKCommunity acquired" exact="respiratory" post="and gastrointestinal viral infections: challenges in the immunocompromised hostCurr"/>
  <result pre="treatment for 2019-nCoV lung injuryLancet20203951022347347510.1016/S0140-6736(20)30317-232043983 31.KaltsasASepkowitzKCommunity acquired respiratory and gastrointestinal" exact="viral" post="infections: challenges in the immunocompromised hostCurr Opin Infect Dis20122542343010.1097/QCO.0b013e328355660b22766648"/>
  <result pre="in the immunocompromised hostCurr Opin Infect Dis20122542343010.1097/QCO.0b013e328355660b22766648 32.HuiDSAzharEIKimY-Jet al.Middle East" exact="respiratory" post="syndrome coronavirus: risk factors and determinants of primary, household,"/>
  <result pre="the immunocompromised hostCurr Opin Infect Dis20122542343010.1097/QCO.0b013e328355660b22766648 32.HuiDSAzharEIKimY-Jet al.Middle East respiratory" exact="syndrome" post="coronavirus: risk factors and determinants of primary, household, and"/>
  <result pre="Dis201818e217e22710.1016/S1473-3099(18)30127-029680581 33.ZhouFYuTDuRet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="2020. 37.MaW-TYaoX-TPengQet al.The protective and pathogenic roles of IL-17 in" exact="viral" post="infections: friend or foe?Open Biol2019919010910.1098/rsob.19010931337278 38.FaureEPoissyJGoffardAet al.Distinct immune response"/>
  <result pre="from bench to bedside?PLoS ONE20149e8871610.1371/journal.pone.008871624551142 39.JossetLMenacheryVDGralinskiLEet al.Cell host response to" exact="infection" post="with novel human coronavirus EMC predicts potential antivirals and"/>
  <result pre="with SARS coronavirusmBio.20134e00165e111310.1128/mBio.00165-1323631916 40.XuZShiLWangYet al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med20208442042210.1016/S2213-2600(20)30076-X32085846 41.Hawill B, Geraci J"/>
  <result pre="SARS coronavirusmBio.20134e00165e111310.1128/mBio.00165-1323631916 40.XuZShiLWangYet al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med20208442042210.1016/S2213-2600(20)30076-X32085846 41.Hawill B, Geraci J (2020)"/>
  <result pre="(2020) Repurposing dupilumab may treat advanced COVID-19 patients with severe" exact="acute" post="respiratory syndrome by mitigating cytokine storm. 10.31219/osf.io/hk7ep 42.RichardsonPGriffinITuckerCet al.Baricitinib"/>
  <result pre="Repurposing dupilumab may treat advanced COVID-19 patients with severe acute" exact="respiratory" post="syndrome by mitigating cytokine storm. 10.31219/osf.io/hk7ep 42.RichardsonPGriffinITuckerCet al.Baricitinib as"/>
  <result pre="dupilumab may treat advanced COVID-19 patients with severe acute respiratory" exact="syndrome" post="by mitigating cytokine storm. 10.31219/osf.io/hk7ep 42.RichardsonPGriffinITuckerCet al.Baricitinib as potential"/>
  <result pre="cytokine storm. 10.31219/osf.io/hk7ep 42.RichardsonPGriffinITuckerCet al.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 43.SanchezGAMReinhardtARamseySet al.JAK1/2 inhibition with baricitinib in the"/>
  <result pre="storm. 10.31219/osf.io/hk7ep 42.RichardsonPGriffinITuckerCet al.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 43.SanchezGAMReinhardtARamseySet al.JAK1/2 inhibition with baricitinib in the treatment"/>
  <result pre="of autoinflammatory interferonopathiesJ Clin Invest20181283041305210.1172/JCI9881429649002 44.HuiDSSystemic corticosteroid therapy may delay" exact="viral" post="clearance in patients with Middle East respiratory syndrome coronavirus"/>
  <result pre="therapy may delay viral clearance in patients with Middle East" exact="respiratory" post="syndrome coronavirus infectionAm J Respir Crit Care Med201819770070110.1164/rccm.201712-2371ED29227752 45.World"/>
  <result pre="may delay viral clearance in patients with Middle East respiratory" exact="syndrome" post="coronavirus infectionAm J Respir Crit Care Med201819770070110.1164/rccm.201712-2371ED29227752 45.World Health"/>
  <result pre="Crit Care Med201819770070110.1164/rccm.201712-2371ED29227752 45.World Health Organization. Clinical management of severe" exact="acute" post="respiratory infection when COVID-19 is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 1"/>
  <result pre="Care Med201819770070110.1164/rccm.201712-2371ED29227752 45.World Health Organization. Clinical management of severe acute" exact="respiratory" post="infection when COVID-19 is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 1 Apr"/>
  <result pre="Med201819770070110.1164/rccm.201712-2371ED29227752 45.World Health Organization. Clinical management of severe acute respiratory" exact="infection" post="when COVID-19 is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 1 Apr 2020."/>
 </snippets>
</snippetsTree>
